Gleyson Kleber do Amaral-Silva1, Celeste Sánchez-Romero1, Vivian Petersen Wagner2, Manoela Domingues Martins2, Hélder Antônio Rebelo Pontes3, Eduardo Rodrigues Fregnani4, Fernando Augusto Soares5, Oslei Paes de Almeida1, André Caroli Rocha6, Alan Roger Santos-Silva1, Felipe Paiva Fonseca7, Pablo Agustin Vargas8. 1. Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil. 2. Department of Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. 3. Service of Buccal Pathology, João de Barros Barreto University Hospital, Federal University of Pará, Belém, Brazil. 4. Oral Medicine Department, Sírio-Libanês Hospital, São Paulo, Brazil. 5. Department of Pathology, A. C. Camargo Cancer Center, São Paulo, Brazil. 6. Medical School, Clinics Hospital, University of São Paulo, São Paulo, Brazil. 7. Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 8. Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil. Electronic address: pavargas@fop.unicamp.br.
Abstract
OBJECTIVE: The aim of this study was to investigate hMutS proteins in developing human tooth, ameloblastomas, and ameloblastic carcinoma and to determine whether the expression of these proteins has any prognostic potential. STUDY DESIGN: Ten cases of developing human tooth, 39 ameloblastomas, and 2 ameloblastic carcinomas were used to determine the distribution of the proteins during the process of carcinogenesis. Simultaneously, another sample of 73 ameloblastomas was arranged in tissue microarray, and their clinical, microscopic, and radiographic features; treatment outcome; presence of BRAF-V600E mutation; and follow-up data were assessed to determine the prognostic relevance of the expression of hMutS (hMSH2, hMSH3, hMSH6) and Ki-67. hMSH2 and hMSH6 were significantly downexpressed in ameloblastomas (P = .0059) compared with developing human tooth (P < .0001). RESULTS: hMSH2, hMSH3 expression were significantly associated with BRAF-V600E mutation (P < .05). Simultaneous overexpression of hMutS was associated with recurrence (P = .035); however, these did not predict the disease-free survival of patients (P > .05). CONCLUSIONS: hMutS proteins are downregulated in ameloblastoma; moreover, simultaneous overexpression of these proteins in ameloblastoma was associated with recurrence but did not predict disease-free survival.
OBJECTIVE: The aim of this study was to investigate hMutS proteins in developing human tooth, ameloblastomas, and ameloblastic carcinoma and to determine whether the expression of these proteins has any prognostic potential. STUDY DESIGN: Ten cases of developing human tooth, 39 ameloblastomas, and 2 ameloblastic carcinomas were used to determine the distribution of the proteins during the process of carcinogenesis. Simultaneously, another sample of 73 ameloblastomas was arranged in tissue microarray, and their clinical, microscopic, and radiographic features; treatment outcome; presence of BRAF-V600E mutation; and follow-up data were assessed to determine the prognostic relevance of the expression of hMutS (hMSH2, hMSH3, hMSH6) and Ki-67. hMSH2 and hMSH6 were significantly downexpressed in ameloblastomas (P = .0059) compared with developing human tooth (P < .0001). RESULTS:hMSH2, hMSH3 expression were significantly associated with BRAF-V600E mutation (P < .05). Simultaneous overexpression of hMutS was associated with recurrence (P = .035); however, these did not predict the disease-free survival of patients (P > .05). CONCLUSIONS: hMutS proteins are downregulated in ameloblastoma; moreover, simultaneous overexpression of these proteins in ameloblastoma was associated with recurrence but did not predict disease-free survival.
Authors: R Bologna-Molina; V Pereira-Prado; C Sánchez-Romero; G Tapia-Repetto; S Soria; M Hernandez; R Gónzalez-Gónzalez; M Molina-Frechero; T Mikami Journal: Med Oral Patol Oral Cir Bucal Date: 2018-03-01